ProKidney Corp.
PROK
$1.75
-$0.03-1.69%
NASDAQ
Corporate Info
Website
Phone Number
336 999 7019
Address
2000 Frontis Plaza Boulevard
Suite 250
Winston-Salem, NC 27103
Suite 250
Winston-Salem, NC 27103
Country
United States
Year Founded
2015
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
Business Description
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.